New drug LG-0317 tested in people for the first time
NCT ID NCT07522970
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage study is the first time LG-0317 is given to humans. It involves 100 healthy Chinese adults aged 18-45 to check the drug's safety and how the body processes it. Participants receive either the drug or a placebo in single or multiple doses. The goal is to gather safety data before moving to larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LG-0317
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Xuhui Central Hospital
RECRUITINGShanghai, Shanghai Municipality, 200237, China
Contact Phone: •••-•••-•••• Email: •••••@•••••